Results 11 to 20 of about 2,987,261 (338)

Expression of Foxp3 in colorectal cancer but not in Treg cells correlates with disease progression in patients with colorectal cancer [PDF]

open access: yes, 2013
Background: Regulatory T cells (Treg) expressing the transcription factor forkhead-box protein P3 (Foxp3) have been identified to counteract anti-tumor immune responses during tumor progression. Besides, Foxp3 presentation by cancer cells itself may also
A Ho-Pun-Cheung   +45 more
core   +15 more sources

A Quantitative Modular Modeling Approach Reveals the Effects of Different A20 Feedback Implementations for the NF-kB Signaling Dynamics

open access: yesFrontiers in Physiology, 2020
Signaling pathways involve complex molecular interactions and are controled by non-linear regulatory mechanisms. If details of regulatory mechanisms are not fully elucidated, they can be implemented by different, equally reasonable mathematical ...
Janina Mothes   +5 more
doaj   +1 more source

Gene expression in circulating tumor cells reveals a dynamic role of EMT and PD-L1 during osimertinib treatment in NSCLC patients

open access: yesScientific Reports, 2021
Liquid biopsy is a tool to unveil resistance mechanisms in NSCLC. We studied changes in gene expression in CTC-enriched fractions of EGFR-mutant NSCLC patients under osimertinib.
Aliki Ntzifa   +5 more
doaj   +1 more source

Circulating tumor cells in genitourinary tumors [PDF]

open access: yesTherapeutic Advances in Urology, 2017
Management of advanced urogenital malignancies has profoundly changed in recent years due to the development of novel targeted drugs that have significantly improved patient’s clinical outcomes. This process has been made possible mainly thanks to better knowledge of tumor genetic alterations and molecular altered pathways.
Massari, Francesco   +8 more
openaire   +4 more sources

Detection and relevance of epigenetic markers on ctDNA: recent advances and future outlook

open access: yesMolecular Oncology, 2021
Liquid biopsy, a minimally invasive approach, is a highly powerful clinical tool for the real‐time follow‐up of cancer and overcomes many limitations of tissue biopsies.
Evi Lianidou
doaj   +1 more source

Evaluation of Monocarboxylate Transporter 4 (MCT4) Expression and Its Prognostic Significance in Circulating Tumor Cells From Patients With Early Stage Non-Small-Cell Lung Cancer

open access: yesFrontiers in Cell and Developmental Biology, 2021
Purpose: Monocarboxylate transporter 4 (MCT4) can influence the amount of lactate in the tumor microenvironment and further control cancer cell proliferation, migration, and angiogenesis.
Athina Markou   +6 more
doaj   +1 more source

Tumor-reactive immune cells protect against metastatic tumor and induce immunoediting of indolent but not quiescent tumor cells [PDF]

open access: yes, 2016
Two major barriers to cancer immunotherapy include tumor-induced immune suppression mediated by myeloid-derived suppressor cells and poor immunogenicity of the tumor-expressing self-antigens.
Bear, Harry D.   +8 more
core   +2 more sources

CTC-Derived Models: A Window into the Seeding Capacity of Circulating Tumor Cells (CTCs)

open access: yesCells, 2019
Metastasis is the main cause of cancer-related death owing to the blood-borne dissemination of circulating tumor cells (CTCs) early in the process.
Tala Tayoun   +5 more
doaj   +1 more source

Extracellular Matrix Protein Tenascin C Increases Phagocytosis Mediated by CD47 Loss of Function in Glioblastoma. [PDF]

open access: yes, 2019
Glioblastomas (GBM) are highly infiltrated by myeloid-derived innate immune cells that contribute to the immunosuppressive nature of the brain tumor microenvironment (TME).
Gao, Peisong   +14 more
core   +2 more sources

Osteocyte-Driven Downregulation of Snail Restrains Effects of Drd2 Inhibitors on Mammary Tumor Cells [PDF]

open access: yes, 2018
While bone is a frequent target of breast cancer-associated metastasis, little is known about the effects of tumor-bone interactions on the efficacy of tumor-suppressing agents.
Chen, Andy   +8 more
core   +1 more source

Home - About - Disclaimer - Privacy